#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paget's disease of the vulva Pleural mesothelioma malignant Emphysema Pleural mesothelioma Thrombotic thrombocytopenic purpura Precursor T-lymphoblastic lymphoma/leukaemia recurrent Dermatomyositis Mucopolysaccharidosis II Follicular lymphoma stage I Haemophilia A with anti factor VIII Heritable pulmonary arterial hypertension Cognitive disorder Myeloid leukaemia CDKL5 deficiency disorder Cardiac arrest More trials…

    Learn about Rare Diseases

    Lymphatic malformation Ewing’s sarcoma – Diagnostics Hepatic angiosarcoma – Treatment Primary hyperoxaluria – Trials in Disease Waldenstrom’s macroglobulinaemia – Diagnostics SAPHO syndrome Mucous membrane pemphigoid – Life with Disease Hairy cell leukaemia – Diagnostics Wolfram syndrome Adrenogenital syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fosfomycin Formoterol Fumarate Dihydrate Albaconazole Saline Dexketoprofen Trometamol Sacituzumab Govitecan Kan-101 Estradiol Hemihydrate Xanthum Gum Florbetapir (18F) Ciprofloxacin Pirfenidone IHMA-2121771-2 DUVELISIB Finasteride Rosuvastatin Calcium Betaxolol Rilzabrutinib Paracetamol Ustekinumab More therapies…

    Learn about Your Condition

    Ewing's sarcoma recurrent Hypersomnia Connective tissue disorder Diphtheria Neurodegenerative disorder Foot deformity Myelofibrosis Adenocarcinoma Neuromyopathy Haemoglobinuria Bone marrow failure Diabetic foot Eye disorder Hypertrophic cardiomyopathy Gingival bleeding More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myasthenia gravis

  • Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

    Recruiting

    2 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Povetacicept
    Poland

  • A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

    Recruiting

    2 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    • Empasiprubart
    Belgium Germany Greece Italy The Netherlands Poland +1

  • A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

    Recruiting

    1 1 1
    Investigated Drugs:
    • HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE
    • HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM PHOSPHATE [PRODUCED IN S. CEREVISAE CELLS BY RDNA]
    • MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
    Bulgaria Italy Poland Spain

  • Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Cladribine
    • Recombinant Varicella Zoster Virus Glycoprotein E
    Belgium Bulgaria Czechia France Germany Greece +6

  • A study testing how inebilizumab works and how safe it is in children and teenagers aged 2 to 17 years with generalized myasthenia gravis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Inebilizumab
    France Italy Poland Spain

  • Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

    Recruiting

    3 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • IMEROPRUBART
    Czechia Denmark Germany Greece Hungary Italy +3
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!